Suzette Kox, MPharm: Bridging Studies and Biosimilars
Suzette Kox, MPharm, secretary general of the International Generic and Biosimilar Medicines Association (IGBA), discusses the need to waive bridging studies in biosimilar development.
Transcript
We need to make really substantial progress on waiving of bridging studies where the comparator products used are just another version of the local reference product.
So how are we going to do that? I think we have of course the excellent publication of Christopher J. Webster and Gillian R. Woollett, DPhil, which has laid the scientific basis for this reflection that eventually we have only 1 comparator product on the market, which should be the basis for the biosimilar development. That’s one thing.
But how do we get this forward? Because the science is there, because these products are based on the same clinical data package, even versions which are on the market around the world. I think what we are probably going to do is of course we’ve had some interaction with some agencies. We’ll further talk about it at different conferences to get the ball rolling, keep the momentum.
It should be a key priority for the [IPRP, the International Pharmaceutical Regulators Program], there is a biosimilar working party, and the IPRP (it was formerly IPRF); this is for me the largest forum for the moment where biosimilars are discussed, and it should be a key priority to look into that.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
